Research programme: menorrhagia therapeutics - XenoPortAlternative Names: Tranexamic acid prodrug; XP 21510
Latest Information Update: 27 Mar 2012
At a glance
- Originator XenoPort
- Mechanism of Action Plasminogen activator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Menorrhagia
Most Recent Events
- 27 Mar 2012 Suspended - Preclinical for Menorrhagia in USA (PO)
- 31 Jul 2009 XP 21510 is no longer licensed to Xanodyne Pharmaceuticals in USA
- 31 Oct 2008 Preclinical development is ongoing for Menorrhagia in USA